American Society of Nephrology (ASN) Annual Meeting 2026
Pharmacokinetic, pharmacodynamic, and exposure–response analysis of pegcetacoplan in C3G and primary IC-MPGN
User experience with pegcetacoplan on-body injector in patients with C3 glomerulopathy or primary immune-complex membranoproliferative glomerulonephritis
Epidemiology of focal segmental glomerulosclerosis: A systematic review of studies published from 2020 to 2025
Humanistic burden of focal segmental glomerulosclerosis: Findings from a systematic review
Evaluation of pegcetacoplan in adults and adolescents with focal segmental glomerulosclerosis: Rationale and design of a sequential phase 2/3 study
Renal safety of pegcetacoplan in paroxysmal nocturnal hemoglobinuria (PNH): Findings from clinical trials and global real-world experience
The following information is available for educational purposes only. The information is not to be re-purposed or re-used in its current form or presentation for any personal or professional use. Apellis reserves the right to withdraw, modify or change the information that is available on this website at any time.
